AzurRx BioPharma Inc (NASDAQ:AZRX)’s stock price traded down 11.3% during trading on Thursday . The company traded as low as $0.46 and last traded at $0.47, 555,162 shares were traded during trading. An increase of 207% from the average session volume of 180,758 shares. The stock had previously closed at $0.53.
A number of equities analysts have recently commented on the stock. HC Wainwright reduced their price objective on shares of AzurRx BioPharma from $6.00 to $5.00 and set a “buy” rating for the company in a report on Thursday, September 26th. ValuEngine raised shares of AzurRx BioPharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Seven analysts have rated the stock with a buy rating, AzurRx BioPharma currently has a consensus rating of “Buy” and a consensus target price of $7.25.
The business’s fifty day moving average price is $0.90 and its 200 day moving average price is $1.64. The company has a market capitalization of $12.40 million, a P/E ratio of -0.54 and a beta of 2.09.
Several large investors have recently added to or reduced their stakes in AZRX. Royal Bank of Canada bought a new position in shares of AzurRx BioPharma during the 2nd quarter worth about $48,000. JPMorgan Chase & Co. bought a new position in shares of AzurRx BioPharma during the 2nd quarter worth about $57,000. BlackRock Inc. lifted its holdings in shares of AzurRx BioPharma by 57.6% during the 2nd quarter. BlackRock Inc. now owns 42,313 shares of the company’s stock worth $72,000 after acquiring an additional 15,463 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of AzurRx BioPharma by 255.0% during the 2nd quarter. Vanguard Group Inc. now owns 260,306 shares of the company’s stock worth $443,000 after acquiring an additional 186,985 shares during the period. 12.12% of the stock is owned by institutional investors.
About AzurRx BioPharma (NASDAQ:AZRX)
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
Read More: Are we seeing the beginning of a new bubble?
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.